This clears the fog fir me on why we are trying to compare ourselves to other existing tech. I was concerned the developers of drugs seem to create their own cell penetrating tech at the same time, but if we can show them that a specialized fpp tech company can make their developed drug way more efficient or cheaper or less toxic due to lower dose they could well be interested, and may be prepared to swap out their second rate cpp. They obviously already know how valuable cell penetration is and how crucial to their existing product
Ann: First Competitive Read Out - Peptide Vaccine, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.005(0.40%) |
Mkt cap ! $731.9M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.29 | $1.19 | $429.5K | 349.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4016 | $1.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |